Redhill Biopharma Ltd., a foreign private issuer, has successfully passed a resolution to increase its authorized share capital at the Extraordinary General Meeting of Shareholders held on March 21, 2024. The resolution was approved by the company's shareholders, as reported in the Form 6-K filed with the United States Securities and Exchange Commission. This corporate action is now incorporated by reference into the company's various Registration Statements on Forms S-8 and F-3, which have been previously filed with the SEC on specified dates ranging from May 2, 2013, to October 13, 2023. The Form 6-K serves as a legal document that ensures the company adheres to the SEC regulations by providing timely updates on significant corporate events.

Redhill Biopharma Ltd., a foreign private issuer, has successfully passed a resolution to increase its authorized share capital at the Extraordinary General Meeting of Shareholders held on March 21, 2024. The resolution was approved by the company's shareholders, as reported in the Form 6-K filed with the United States Securities and Exchange Commission. This corporate action is now incorporated by reference into the company's various Registration Statements on Forms S-8 and F-3, which have been previously filed with the SEC on specified dates ranging from May 2, 2013, to October 13, 2023. The Form 6-K serves as a legal document that ensures the company adheres to the SEC regulations by providing timely updates on significant corporate events.